GW7604

Endocrine / ER antagonist

Breast cancer endocrine research positioning

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: SERM/SERD-like metabolite
Primary mechanism: Active metabolite with ER antagonism/degradation-like activity
Primary market use: Oncology / endocrine research

Pharmacology

Molecular weight (Da): Not consistently disclosed
Oral bioavailability: Not established
Half-life: ~1–12 h provisional PK estimate
Route tags: Route-dependent / verify
Evidence level: Preclinical
Clinical status: Research
Value-for-money score: 2 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Often discussed with GW5638/etacstil; sparse standalone PK

Sources

https://pubchem.ncbi.nlm.nih.gov/#query=GW7604